Approval · Notice of Compliance 13824 · 2012
SANDOMIGRAN: Notice of Compliance 13824
Issued November 5, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13824
- Date
- November 5, 2012
- Company
- Paladin Labs Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Major update to the Product Monograph including the Indication, Warnings & Precautions, Dosage and Administration and creation of Part III
- Therapeutic class
- Migraine prophylaxis
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SANDOMIGRAN | Not yet assigned | — |
| SANDOMIGRAN DS | Not yet assigned | — |
Medicinal ingredients
- PIZOTIFEN MALATE 0.5 MG per TAB
- PIZOTIFEN MALATE 1 MG per TAB